Faricimab meets primary endpoints in phase 3 wet AMD studies
Click Here to Manage Email Alerts
Faricimab met its primary endpoint in two phase 3 studies, with injections every 16 weeks achieving noninferior visual acuity outcomes compared to aflibercept every 8 weeks in wet age-related macular degeneration, according to a press release.
In the TENAYA and LUCERNE studies, 45% of participants were dosed with faricimab (Genentech) every 16 weeks in the first year. Subjects achieved noninferior visual acuity outcomes compared with patients who received Eylea (aflibercept, Regeneron) injections every 8 weeks, the release said. In addition, faricimab presented no new or unexpected safety signals.
The identical, randomized, multicenter, double-masked, global studies are evaluating the efficacy and safety of faricimab in 1,329 subjects with wet AMD.
“We have now seen positive and consistent results in four phase 3 studies for faricimab across both neovascular age-related macular degeneration and diabetic macular edema,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in the release. “We look forward to submitting these data to global regulatory authorities, with the aim of bringing this promising treatment option to patients as soon as possible.”
Positive results were reported earlier for the YOSEMITE and RHINE phase 3 studies in diabetic macular edema.
Read more about
Click Here to Manage Email Alerts